Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes. 2017

Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.

OBJECTIVE Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. METHODS We measured MBL, fructosamine, and HbA1cat baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. RESULTS After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P < 0.0001). There was a significant decrease in HbA1c from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P < 0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P < 0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919-3389 μg/L) at baseline to 1928 μ/L (IQR 811-2758 μg/L) at follow-up (P = 0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA1c, or fructosamine. CONCLUSIONS MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007332 Insulin Infusion Systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. Pancreas, Artificial Endocrine,Programmable Implantable Insulin Pump,beta Cell, Artificial,Implantable Programmable Insulin Pump,Insulin Pump, Programmable Implantable,Pump, Programmable Implantable Insulin,Artificial Endocrine Pancreas,Artificial beta Cell,Artificial beta Cells,Cell, Artificial beta,Cells, Artificial beta,Endocrine Pancreas, Artificial,Infusion System, Insulin,Infusion Systems, Insulin,Insulin Infusion System,System, Insulin Infusion,Systems, Insulin Infusion,beta Cells, Artificial
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002138 Calibration Determination, by measurement or comparison with a standard, of the correct value of each scale reading on a meter or other measuring instrument; or determination of the settings of a control device that correspond to particular values of voltage, current, frequency or other output. Calibrations
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
October 2003, The Journal of clinical endocrinology and metabolism,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
May 2015, Clinical and experimental immunology,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
June 2005, Clinical evidence,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
May 2011, BMJ clinical evidence,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
June 2006, Clinical evidence,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
July 2008, BMJ clinical evidence,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
January 2016, Journal of diabetes research,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
March 1983, British medical journal (Clinical research ed.),
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
January 2013, Journal of Ayub Medical College, Abbottabad : JAMC,
Gry Høst Dørflinger, and Charlotte Brink Holt, and Steffen Thiel, and Jakob Appel Østergaard, and Troels Krarup Hansen
March 2013, Scandinavian journal of immunology,
Copied contents to your clipboard!